Powerhouse Ventures Ltd. · ASX:PVL
Powerhouse Ventures — Investor Presentation (May 2017)
92 slides from Powerhouse Ventures's investor presentation, May 12, 2017
Slide 1: Powerhouse Ventures Limited Portfolio Showcase Briefings
For personal use only Powerhouse Ventures Limited (ASX code:PVL) Portfolio Showcase Briefings www.powerhouse-ventures.co.nz
Slide 2: Briefing dates and venues
2 For personal use only Australia Sydney Melbourne Monday 15 May 2017 Tuesday 16 May 2017 Commence at 4.30pm Commence at 4.30pm The Press Room The Wine Room The Radisson Blu Plaza Sydney The Westin Melbourne 27 O’Connell Street 205 Collins Street Sydney, NSW 2000 Melbourne, VIC 3000 New Zealand Quee
Slide 3: Disclaimer
3 For personal use only Disclaimer The information in this presentation is not an offer, nor constitutes investment advice or any recommendation to subscribe or acquire securities or retain or sell any securities currently held in Powerhouse Ventures Limited or any of the portfolio companies represe
Slide 4: Agenda
4 For personal use only Opening remarks – Dr Stephen Hampson AGENDA Registration Powerhouse overview Healthcare Avalia Immunotherapies Upstream Medical Technologies Agritech CropLogic Veritide Invert Robotics Closing remarks
Slide 5: Transforming intellectual property into world-changing businesses
For personal use only Transforming intellectual property into world- changing businesses by following a proven investment pathway
Slide 6: A patient capital investment model
6 For personal use only A patient capital investment model 5–10 new Test proof of concept Early revenues (DUO\SUR¿WVEHIRUH investments growth Recruit management Develop business per year team (often includes model Prepare for liquidity Powerhouse team event embedded) $ $$$ ~2 years ~2 years ~2 years
Slide 7: Powerhouse creates companies that solve important global problems
For personal use only Powerhouse creates companies that solve important global problems
Slide 8: Healthcare Sector
8 For personal use only Healthcare Sector More than 50% of the world population lives with chronic disease Cancer is one of the world's biggest killers, with ~14m new cases per year – ground-breaking new therapeutic cancer vaccine Cardiovascular diseases account for 31% of all deaths worldwide – ear
Slide 9: Avalia Immunotherapies
For personal use only Avalia Immunotherapies Melissa Yiannoutsos, Executive Director
Slide 10: Avalia Immunotherapies Limited
MAY 2017 For personal use only AVALIA IMMUNOTHERAPIES LIMITED HARNESSING THE POWER OF YOUR IMMUNE SYSTEM TO CURE CANCER AND PREVENT DISEASE
Slide 11: Avalia overview
2 For personal use only 1. Preclinical stage immuno-oncology } company Avalia will become a leading 2. Founded on decades of research in the supplier of vaccines that field of natural killer T cells 3. Proprietary vaccine technology platform stimulate important immune protected by four patent famili
Slide 12: Most promising area of oncology treatment
Avalia Immunotherapies operates in the most promising area of oncology treatment TREATING CANCER WITH IMMUNOTHERAPY 3 For personal use only In 2016, the cancer immunotherapies market reached $73 billion and is forecast to grow by LOCALISED 5.7% CAGR to reach $96.5 billion in 2021. Types of administr
Slide 13: Resurgence of therapeutic cancer vaccines
RESURGENCE OF For personal use only THERAPEUTIC CANCER VACCINES • Tumour or whole cell vaccines • Vector based vaccines • Nucleotide based vaccines • Protein or peptide vaccines Avalia’s focus on peptide vaccines is driven by its demonstrated ability to activate key immune cells that drive robust, l
Slide 14: First product for HPV-related cancers
For personal use only Avalia’s first product is showing promise in the treatment of cancers for the many patients infected with the human papillomavirus (HPV). HPV is a common sexually transmitted virus that can trigger the onset of many incurable cancers including cervical and head & neck.
Slide 15: HPV infection and cancer rates are high
Avalia Immunotherapies HPV INFECTION AND CANCER RATES ARE HIGH 6 For personal use only PREVENTATIVE VACCINES EVERY DAY IN THE USA: CERVICAL INTRAEPITHELIAL 12,000 2,600 NEOPLASIA (CIN) Global incidence > 15-24 year olds are of those are infected with 500,000 infected with HPV HPV16, which is Standar
Slide 16: Our ability to compete in HPV cancer treatment
Avalia Immunotherapies OUR ABILITY TO COMPETE IN HPV CANCER TREATMENT SETTING 7 For personal use only Avalia vaccines enhance In industry standard TC-1 model antigen specific cell killing Avalia vaccines reduce tumour growth → Ability to activate important immune cells to achieve a lasting anti-tumo
Slide 17: Avalia investment highlights: progression towards the clinic
Avalia Immunotherapies’ investment highlights PROGRESSION TOWARDS THE CLINIC FOR FIRST PRODUCT 8 For personal use only 2015 2017 1 2 3 4 5 8 INVESTMENT PRECLINICAL GOOD SAFETY PHASE I STUDY GRANTED PATENTS INVESTMENT Investment from EFFICACY Preliminary safety DESIGN First of Avalia’s patent Oversub
Slide 18: Activating the immune system
Activating the immune system HOW AVALIA’S IMMUNOTHERAPY WORKS? 9 For personal use only Cytokines Antigen Adjuvant Natural killer T (NKT) cells are a special immune cell that help drive a powerful tumour-fighting response that is complementary and in some settings superior to other treatment approach
Slide 19: Proprietary platform technology: IP portfolio
Avalia Immunotherapies proprietary platform technology INTELLECTUAL PROPERTY PORTFOLIO 10 For personal use only PATENT COVERAGE PATENTS CORE IP Sphingoglycolipid compounds and uses / Organic compounds PRIORITY DATE: 2012 Granted in NZ, US, pending in Canada, Europe, Japan, Australia, China Korea, In
Slide 20: Research partners
Avalia Immunotherapies RESEARCH PARTNERS 11 For personal use only AVALIA HAS The Ferrier Research Institute was recently awarded a major Government research contract for 5 years. The targeted research programme focuses on the manufacture of self- RESEARCH adjuvanting peptide vaccines for cancer and
Slide 21: Avalia growing pipeline
Avalia Immunotherapies’ growing pipeline VACCINE DISCOVERY AND DEVELOPMENT 12 For personal use only Discovery Lead Preclinical Phase I Phase II Optimization AVA1001 HPV-DRIVEN CANCERS AVA1001 PERSONALISED VACCINES AVA1002 SOLID TUMOURS AVA2001 AVA2002 INFECTIOUS DISEASE
Slide 22: Capital plan
Avalia Immunotherapies CAPITAL PLAN 13 For personal use only FUNDING TO DATE FUTURE CAPITAL Pre-seed investment ROUND CAPITAL USE OF FUNDS Founding institutes Series A > $5 million o Regulatory safety studies Powerhouse PHASE I o Vaccine manufacture for Phase I study New Zealand Venture Investment F
Slide 23: Adaptable, ease of manufacture, best-in-class treatments
14 For personal use only ADAPTABLE } Avalia’s vaccines engage key components of our immune EASE OF MANUFACTURE systems to generate potent, robust, targeted and durable T PATENT PORTFOLIO cell responses, which have the potential to translate to superior responses in the treatment of BEST-IN-CLASS can
Slide 24: Upstream Medical Technologies
For personal use only Upstream Medical Technologies Ruth Appleby, Chief Executive Officer
Slide 25: Advanced Diagnostics for Acute Cardiac Care
Advanced For personal use only Diagnostics For Acute Cardiac Care
Slide 26: The Vision
The Vision: For personal use only Upstream Medical Technologies will become a global leader in the development and commercialisation of next generation biomarkers; delivering sustainable and substantial benefits to patient outcomes, healthcare delivery and shareholders.
Slide 27: Upstream Medical Technologies at a glance
Upstream Medical Technologies —At A Glance For personal use only Upstream’s The Upstream is Upstream has current funding addressable planning for developed round will provide market for registration of its a world-leading a reasonable Unstable Unstable Angina cardiovascular runway to the next Angina
Slide 28: Upstream Medical Technologies at a glance
Upstream Medical Technologies —At A Glance For personal use only Upstream’s Upstream Signal Peptide Upstream’s Upstream’s acquires technology can prospects for founders complementary be considered as licensing its have scientific diagnostics where a new platform technology credibility. there is clos
Slide 29: The Primary Problem
The Primary Problem: For personal use only Emergency Department (ED) Physicians require rapid and accurate methods to determine which patients require immediate life saving medical treatment when they present with chest pain. The challenge is to determine who is really at risk of a heart attack?
Slide 30: Diagnosis of Heart Attack Risk
Diagnosis of Heart Attack Risk For personal use only Acute coronary syndrome (ACS) is a continuum of artery blockage resulting in ischemia, lack of blood supply. Lumen, where blood flows Lipid Thrombus Platelets Lipid accumulation Plaque 8QVWDEOH$QJLQD +HDUW$WWDFN +HDUW$WWDFN (&*PD\EHQRUPDO (&*PD\EH
Slide 31: How Big Is This Problem?
How Big Is This Problem? For personal use only 8 million 1 in 25 patients in the USA present in is at risk of heart attack but ED with chest pain each year. are not able to be quickly and 2QO\RQHLQHLJKWRIWKHVHFKHVWSDLQSDWLHQWVZLOOEH H[SHULHQFLQJDOLIHWKUHDWHQLQJHYHQWVXFKDVDQDFWXDO easily diagnosed. R
Slide 32: UARatio: A New Way To Manage Heart Attack Risk
UARatio — A New Way To Manage Heart Attack Risk For personal use only The Problem—Using Traditional The Solution—Using UARatio Testing Methods “Watch and Wait” Development by Upstream 12% admitted with possible chest pain patients 4% risk of heart risk of heart attack attack diagnosed 8% heart attac
Slide 33: The Scale Of The Solution
The Scale Of The Solution For personal use only ~8 million patients UARatio could conservatively per annum in the USA save ~8 unnecessary hospital admissions per 100 patients x2 days at ~US$5220/day UARatio would cost UARatio could save over ~US$400 million to ~$6.0 billion in costs to the deploy ac
Slide 34: Built On Strong Foundations
Upstream Medical Technologies — Built On Strong Foundations For personal use only A decade of excellence from within the Christchurch Heart Institute 2006 2016 A wealth of international Clinical trials conducted Over 125 peer-reviewed expertise and scientific with Roche, Abbott, publications over th
Slide 35: A Clearly Defined Pathway Forward
A Clearly Defined Pathway Forward For personal use only UARatio, GHRsp, EPOsp sold UARatio licensed. as Research Use Only. GHRsp 510K and CE Feasibility study of EPOsp UARatio clinical trial marking applications for drug doping monitoring. complete. complete. Investment of $3 million 510K and CE mar
Slide 36: Strategic Business Model: Delivering Early Revenue Streams
Strategic Business Model — Delivering Early Revenue Streams For personal use only Direct Sales Customers Cash flow Advantage Research Use Only Cardiovascular Kit Sales, Immediate and Autoimmune Research and Monoclonal worldwide access. Diagnostics Autoimmune antibody sales Sets market trend Research
Slide 37: Deep Intellectual Property Platform
Deep Intellectual Property Platform For personal use only Heart Attack/ Heart Attack/ Unstable Angina Unstable Angina Background AU, CA, CN, PROV EP, IN, JP, NZ, US Heart 8 patent families directed to human focused Heart Attack/ Unstable Attack/ UA peptide-based diagnostic technologies. Unstable AU,
Slide 38: Agritech Sector
11 For personal use only Agritech Sector World food production must double by 2050 Increasing crop productivity to meet global needs for food – transformational technology for agronomists and growers 47% of food recall is due to microbiological contamination – microbial contamination detection – ind
Slide 39: CropLogic
For personal use only CropLogic Jamie Cairns, Chief Executive Officer
Slide 40: Optimising Crop Yields with Remote Monitoring and Big Data Analytics
For personal use only Optimising Crop Yields with Remote Monitoring and Big Data Analytics Transformational Technology for Agronomists and Growers Transforming the agronomy industry 1
Slide 41: Investment highlights
Investment highlights For personal use only CropLogic uses complex 90% profit increase for potato 01 05 growers achievable from 6.25% modelling and Internet of Things technologies to predict crop overall yield increase yield outcomes and support Technology validated through field agronomic decision
Slide 42: What is the CropLogic System?
What is the CropLogic System and how does it differ from current practices? For personal use only (agronomy + technology) Internet of Things Agronomist CropLogic system CropLogic meets with analyses data system grower and and proposes correlates Recommendations installs probe fertigation proposed pr
Slide 43: The technology
The technology For personal use only Not just a system of probes User management inputs User weather inputs User soil inputs Crop Model Soil Model Demand Supply Predictions Predictions Potential yield Stress Responses Management Schedule 100 80 Output 60 40 20 0 Patent US8671006 Sep Oct Nov Dec Jan
Slide 44: Data validation
Data validation Modelled outputs validate inputs For personal use only 0.32 Volumetric Water Content 0.3 Volumetric Water Content 0.28 Measured 0.32 0.26 Modelled 0.32 0.3 0.24 Volumetric Water Content 0.3 0.22 0.28 Volumetric Water Content 0.28 0.2 0.26 0.18 0.26 0.24 0.24 Date 0.22 Validation incr
Slide 45: Years of research and trials
30 years of research and 5 years of trials For personal use only Over 65,000 acres of trials from 2011 with key food processing companies. United States China 504 field trials, 18 field trials, Lamb Weston PepsiCo 29 field trials, Frito-Lay New Zealand Australia 124 field trials, 2 field trials, McC
Slide 46: Size of target market
Size of target market For personal use only 29 million acres USD $1 Billion Annually 1000 acres or more Target Farms Irrigated cropping farms of 1,000 acres or more At US$35 per acre this is a potential revenue of USD$1 billion per annum. Why USA first? · This is due to relationships 60 million acre
Slide 47: Route to Market
Route to Market For personal use only Acquisition of Agronomist Partnering with Major Service Companies Crop Buyers Organic Growth of Acquisitions Supplemented by Direct Hires Growers Direct Transforming the agronomy industry 8
Slide 48: Top down approach – influencers
Top down approach – influencers For personal use only CropLogic has good relationships with many of the major potato processors globally. These buyers like the CropLogic model for three reasons: Reducing costs Supply-chain management Environmental pressures increasing globalisation of the global pop
Slide 49: CropLogic Revenue
CropLogic Revenue ~ $25-35 For personal use only A Business to Business REVENUE per-acre per-crop recurring subscription model ~ $10 PHASE 2 ~ $25 PER ACRE · CropLogic System REVENUE PREDICTIVE SERVICES greatly reduces labour and travel costs ~ $5 · CropLogic Systems · Per Acre per annum allows agro
Slide 50: Value for growers
Value for growers Up to 90% increase in bottom line For personal use only END VALUE TO GROWER All figures in $USD Currently With CropLogic Target subscription fees of $25 - $35 Revenue $3,045 $3,235 (+6.25%) per acre per crop Operating Costs Seed $331 $331 Fertilizer and chemicals $702 $690 Water $1
Slide 51: USA Strategic Acquisition
USA Strategic Acquisition For personal use only Provides immediate: Footprint in the Acres under Growth largest USA management – opportunities potato-producing currently approx. region 100,000 · Binding Term Sheet signed November 2016 · Settlement May 2017 · Settlement fee on signing S&P Three-year
Slide 52: Milestones for the next months
Milestones for the next 12 months For personal use only 01 02 03 Appoint broker: $2M pre-IPO raise: USA Acquisition: Done, Hunter Capital Done, April 2017 Done appointed April 2017 04 05 IPO – planned listing Australian/USA Q3 2017 agronomy firm acquisition Transforming the agronomy industry 13
Slide 53: For more information contact
For personal use only For more information contact: Jamie Cairns James Cooper-Jones jamie.cairns@croplogic.com james.cooper-jones@croplogic.com +64 21 645 445 +61 419 978 062 Transforming the agronomy industry 14
Slide 54: Veritide
For personal use only Veritide Ian Hunter, Chief Executive Officer
Slide 55: Shedding New Light on Food Safety
Shedding For personal use only New Light on Food Safety
Slide 56: The Vision
The Vision: For personal use only Veritide’s contamination detection technology and services will become the global, benchmark food safety standard for the meat and poultry processing and distribution industries.
Slide 57: The Problem / The Veritide Solution
The Problem The Veritide Solution For personal use only Low Detection Accuracy/Reliability/Speed High High Consumer Health & Safety Risks Low High Product Recalls Low High Wastage/Product Losses Low Lower Stakeholder Returns Higher High Reputational Risk/Brand Damage Low
Slide 58: Veritide at a glance
Veritide! —!At A Glance For personal use only Setting a new benchmark A proprietary screening in microbial contamination technology platform that detection for the global meat represents a quantum leap and poultry processing and in performance versus distribution industries. current industry practic
Slide 59: Veritide at a glance
Veritide! —!At A Glance For personal use only Value-added services in A simple, globally scalable development to deliver loyal operating model that cascades clients and recurring revenue value through to all stakeholders. streams. An engaged blue-chip client base in target markets.
Slide 60: Investment Synopsis: A Compelling Growth Story
Investment Synopsis —!A Compelling Growth Story For personal use only Investment Attractive Revenue for Growth and Profit Projections — Substantial sales opportunities targeted across — Potential revenues of NZ$30 large meat and poultry supply chains. million by 2021 in target markets. — Significant
Slide 61: A Growing Global Market
A Growing Global Market For personal use only ‘The global food safety testing market is expected to grow to US$15 billion p.a. by 2019.’ The current solutions for faecal detection in the meat and poultry processing sectors are substandard.
Slide 62: The Problem: Food-borne Pathogens
The Problem —!Food-borne Pathogens For personal use only 48m Americans — 48 million Americans fall ill every year as a result of food-borne pathogens. fall ill annually. — US$55 billion: The total annual cost of medical treatment, lost productivity and illness-related morality due to Total costs: fo
Slide 63: The Problem: Microbial Contamination of Meat
The Problem —!Microbial Contamination of Meat For personal use only 47% of recalls: — Faecal matter in meat is home to a variety of dangerous bacteria! microbial —!key among them, E.Coli. — In the USA alone, meat and poultry contamination. account for 85 recalls per annum. — 47% of recalls are due t
Slide 64: Current Solution: Failing All Stakeholders
Current Solution —!Failing All Stakeholders For personal use only Laboratory Visual Intervention Methods Inspections Methods E.g. Swabbing meat samples and E.g. Dedicated personal visually E.g. Acid washes, water washes, testing for the presence of bacteria inspecting in the meat processing facility
Slide 65: Veritide Solution: A Quantum Leap in Contamination Detection
Veritide Solution —!A Quantum Leap in Contamination Detection For personal use only Shedding a new light on food safety Veritide combines: Patented, bacterial Veritide’s patented spore detection technology is technology able to detect both visible and invisible faecal World-class expertise contamina
Slide 66: Cascading Value to the Whole Supply Chain
Veritide —!Cascading Value to the Whole Supply Chain For personal use only Meat Processors/ ! Automated screening at line processing speeds Manufacturer ! Real-time results Meat Inspection Services !Reliable and accurate Quality assurance and ! Environmentally superior services, regulatory agencies,
Slide 67: Market Validated Technology
Market Validated Technology For personal use only Veritide has secured broad industry/stakeholder engagement. ANZCO (NZ meat Meat and Livestock AsureQuality (NZ meat processor) have Australia have inspection company) leased a Conveyor sponsored a study is creating a Customer Hot Spot Scanner using 3
Slide 68: Recurring Revenues Driven Off A Solid Product Platform
Recurring Revenues Driven Off A Solid Product Platform For personal use only Product Revenue Platform Opportunities Primary Developments — Off-the-shelf unit sales or — Hand-held scanners lease options — Hot-spot scanners — Monthly pay-per-use fees — Carcass scanners (e.g. NZ$1.00/beef carcass or NZ
Slide 69: A Strong Intellectual Property Position
A Strong Intellectual Property Position For personal use only Veritide are experts Technology Patent Status in optical techniques NZ542230 Granted for rapidly finding Bacterial Spore US7622723 AU2006288014 Granted Granted food contamination. Detection GB2445488 US8711354 Granted Granted EP2263072 Pe
Slide 70: Invert Robotics
For personal use only Invert Robotics Neil Fletcher, Managing Director
Slide 71: Invert Robotics May 2017
For personal use only INVERT ROBOTICS MAY 2017
Slide 72: The Vision
For personal use only The Vision: Invert Robotics will become a leading global provider of industrial inspection services for mission critical assets. INVERT ROBOTICS May 2017 Confidential This document is not to be distributed to any third party without the written permission of Invert Robotics 2
Slide 73: Invert Robotics at a glance
INVERT ROBOTICS — AT A GLANCE For personal use only 21st Century Proprietary Value add industrial robotic services inspections technology and recurring services platform revenue streams Strong European Blue chip growth and client base international expansion plans 3
Slide 74: Building solid foundations for growth
BUILDING SOLID FOUNDATIONS FOR GROWTH For personal use only International product trials and demonstrations Patented sliding suction commence Rapid European growth pad drive for robot First Australian First aviation inspection James Robertson inspection jobs contracts signed appointed inaugural CEO
Slide 75: The incumbents vs the innovators
For personal use only High Health & Safety Risks Low Yes Specialist personnel required No Low Inspection Accuracy High High Asset downtime Low High Costs Low No Defendable market position Yes Data warehousing/asset No Yes management capability The The incumbents innovators
Slide 76: Distilling down the scale
DISTILLING DOWN THE SCALE For personal use only The Global Testing, The Global Dairy Inspection and and Food Processing Global Inspection Market &HUWL´FDWLRQ,QGXVWU\ Inspections Market by Region 2020 Revenue Target NZD$250 million Europe - $82M NZD$300 billion annually Asia - $72M annually NZD$16,00
Slide 77: Clearly defined market drivers provide confidence
CLEARLY DEFINED MARKET DRIVERS PROVIDE CONFIDENCE For personal use only Current inspection methods fail to deliver on current market drivers Health and Safety is at the top of corporate agendas in boardrooms globally. Reducing risk to human life is a key Improved Food driver for all primary industri
Slide 78: The competitive landscape
THE COMPETITIVE LANDSCAPE For personal use only Current inspection methods place people, products, brands and companies at risk. Competing techniques are dependent on people entering the tanks, often working from ropes or scaffolds who have WRVHDUFKRQDYHUDJHIRUNPWR´QGDVLQJOHFUDFN Often times the ins
Slide 79: Global client base
GLOBAL CLIENT BASE For personal use only Delivering services to 5 of the top 6 global milk processors 9
Slide 80: European region cow's milk output
For personal use only The European region collectively represents the largest cow’s milk output in the world. Following closely behind this is the American and Asian markets. INVERT ROBOTICS May 2017 Confidential This document is not to be distributed to any third party without the written permissio
Slide 81: A focused geographical and sector specific growth plan
A FOCUSED GEOGRAPHICAL AND SECTOR SPECIFIC GROWTH PLAN For personal use only 7KHVFDOHRIWKHGDLU\DQGIRRGSURFHVVLQJVHFWRUDORQHLVVXI´FLHQWO\ODUJHHQRXJKWRGULYH VXEVWDQWLDOUHYHQXHDQGSUR´WVWUHDPVZLWKPRGHVWPDUNHWSHQHWUDWLRQREMHFWLYHV 269,000,000 200,000,000 Oceania produces only 5% of the 816M tonnes of mil
Slide 82: An expanding global footprint
AN EXPANDING GLOBAL FOOTPRINT For personal use only OFFICES OPERATING COUNTRIES PURCHASE ORDERS 12
Slide 83: Future opportunities
FUTURE OPPORTUNITIES For personal use only With further development of platforms and payloads Invert Robotics will unlock both new verticals and new applications within existing verticals Development Leads to… Application Current Status Ultrasonic and Eddy Current Crack Improved + automated crack te
Slide 84: Powerful platform adaptable to new inspection markets
For personal use only With a powerful platform, Invert Robotics is positioned to rapidly adapt the core technology to new inspection markets. INVERT ROBOTICS May 2017 Confidential This document is not to be distributed to any third party without the written permission of Invert Robotics 14
Slide 85: The incumbents vs the innovators
High Health & Safety Risks Low For personal use only Yes Specialist personnel required No Low Inspection Accuracy High High Asset downtime Low High Costs Low No Defendable market position Yes Data warehousing/asset No Yes management capability The The incumbents innovators
Slide 86: Distilling down the scale: aviation
DISTILLING DOWN THE SCALE For personal use only The Global Airline The Global Scheduled Maintenance Market Maintenance Market Beachhead Market 2020 Revenue Target 24,597 planes in C Check rudder NZD$15 billion 2 major the world inspections on scheduled customers NZD$90 billion NZD$245M per maintenan
Slide 87: Securing key clients
SECURING KEY CLIENTS For personal use only In 2017 Invert Robotics launched an Aviation Development Programme Seeking 5 major MROs or airlines to participate in SURJUDPPHGHVLJQHGWRTXDQWLI\PDWHULDODQG´QDQFLDO EHQH´WVRIURERWLFLQVSHFWLRQ 57% of Heavy Invert Robotics is concludingQHJRWLDWLRQVZLWKWKH´UVW
Slide 88: A strengthening intellectual property position
A STRENGTHENING INTELLECTUAL PROPERTY POSITION For personal use only A patented sliding suction Technology Country AppIn No. Grant No. Status system is at the heart of our Sliding suction cups New Zealand 595509 595509 Granted. Next renewal and their application in due 01/10/2016 world-leading inspe
Slide 89: Closing remarks
For personal use only 15 Closing remarks
Slide 90: A new asset class with an attractive risk/return profile
16 For personal use only A new asset class with an attractive risk/return profile 1 Strong links with university partners for high-quality deal flow 2 Proprietary approach to screening and shaping innovation for predictable success 3 A new model for investing, based on the largely untapped value of
Slide 91: The portfolio
17 For personal use only The portfolio Medical & Agritech & Cleantech & Digital & ICT Healthcare Environmental Engineering
Slide 92: Thank you
For personal use only Thank you Contact details: Stephen Hampson Elise Hughan Managing Director MC Partners +64 27 227 9854 Media and Communications stephen.hampson@powerhouse-ventures.co.nz +61 458 855 500 elise.hughan@mcpartners.com.au Paul Viney CFO/Company Secretary Harrison Polites +64 21 084 7
Powerhouse Ventures — Investor Presentation (May 2017) on 6ix